Clinical Trial: A Study of LY3457263 Compared with Placebo in Participants with Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT06897475) titled 'A Study of LY3457263 Compared with Placebo in Participants with Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide' on March 25.

Brief Summary: The purpose of this study is to measure the change in hemoglobin A1c (HbA1c) with LY3457263 compared with placebo in participants with type 2 diabetes who are not at HbA1c goal when treated with a stable dose of semaglutide or tirzepatide. Participation in the study will last about 9 months.

Study Start Date: April, 2025

Study Type: INTERVENTIONAL

Condition: Type 2 Diabetes

Intervention: DRUG: LY3457263

Administered SC

DRUG: Placebo

Administered SC

Recruitment Status: ...